tbResList Print — almon almonertinib

Filters: qv=278, qv2=%, rfv=%

Product

almon almonertinib
Description: <b>Almonertinib</b> is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is chemically designed and manufactured.<br>
<br>
It is mainly used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. The drug is designed to overcome resistance to earlier-generation TKIs and to provide a more potent inhibition of EGFR signaling in tumors.<br>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   Apoptosis↑, 1,   cl‑Casp3↑, 1,   cl‑Casp9↑, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑PI3K↓, 1,  

Migration ⓘ

TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,   eff↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2024Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathwayTeng ChenPMC11322074https://pmc.ncbi.nlm.nih.gov/articles/PMC11322074/0